vs
Side-by-side financial comparison of ADMA BIOLOGICS, INC. (ADMA) and SunOpta Inc. (STKL). Click either name above to swap in a different company.
SunOpta Inc. is the larger business by last-quarter revenue ($205.4M vs $139.2M, roughly 1.5× ADMA BIOLOGICS, INC.). ADMA BIOLOGICS, INC. runs the higher net margin — 35.5% vs 0.4%, a 35.1% gap on every dollar of revenue. On growth, ADMA BIOLOGICS, INC. posted the faster year-over-year revenue change (18.4% vs 16.6%). ADMA BIOLOGICS, INC. produced more free cash flow last quarter ($34.6M vs $12.1M). Over the past eight quarters, ADMA BIOLOGICS, INC.'s revenue compounded faster (30.4% CAGR vs 7.4%).
ADMA Biologics Inc. is a biopharmaceutical enterprise focused on the research, development, manufacturing and commercialization of specialty plasma-derived immunoglobulin therapies. It primarily operates in the United States, catering to patients with primary immunodeficiency and other immune-related disorders, healthcare providers and medical institutions across its core immune health therapeutic segment.
SunOpta, Inc. is a multi-national food and mineral company headquartered in Eden Prairie, Minnesota and founded in 1973 in Canada.
ADMA vs STKL — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $139.2M | $205.4M |
| Net Profit | $49.4M | $816.0K |
| Gross Margin | 63.8% | 12.4% |
| Operating Margin | 45.1% | 3.3% |
| Net Margin | 35.5% | 0.4% |
| Revenue YoY | 18.4% | 16.6% |
| Net Profit YoY | -55.9% | 113.1% |
| EPS (diluted) | $0.20 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $139.2M | — | ||
| Q3 25 | $134.2M | $205.4M | ||
| Q2 25 | $122.0M | $191.5M | ||
| Q1 25 | $114.8M | $201.6M | ||
| Q4 24 | $117.5M | $193.9M | ||
| Q3 24 | $119.8M | $175.9M | ||
| Q2 24 | $107.2M | $169.5M | ||
| Q1 24 | $81.9M | $184.4M |
| Q4 25 | $49.4M | — | ||
| Q3 25 | $36.4M | $816.0K | ||
| Q2 25 | $34.2M | $4.4M | ||
| Q1 25 | $26.9M | $4.8M | ||
| Q4 24 | $111.9M | $-8.7M | ||
| Q3 24 | $35.9M | $-6.2M | ||
| Q2 24 | $32.1M | $-5.3M | ||
| Q1 24 | $17.8M | $2.9M |
| Q4 25 | 63.8% | — | ||
| Q3 25 | 56.3% | 12.4% | ||
| Q2 25 | 55.1% | 14.8% | ||
| Q1 25 | 53.2% | 15.0% | ||
| Q4 24 | 53.9% | 10.9% | ||
| Q3 24 | 49.8% | 13.0% | ||
| Q2 24 | 53.6% | 12.5% | ||
| Q1 24 | 47.8% | 16.8% |
| Q4 25 | 45.1% | — | ||
| Q3 25 | 38.0% | 3.3% | ||
| Q2 25 | 35.1% | 5.5% | ||
| Q1 25 | 30.4% | 5.2% | ||
| Q4 24 | 32.6% | 1.4% | ||
| Q3 24 | 33.1% | 0.5% | ||
| Q2 24 | 36.6% | 1.2% | ||
| Q1 24 | 26.7% | 5.5% |
| Q4 25 | 35.5% | — | ||
| Q3 25 | 27.1% | 0.4% | ||
| Q2 25 | 28.1% | 2.3% | ||
| Q1 25 | 23.4% | 2.4% | ||
| Q4 24 | 95.2% | -4.5% | ||
| Q3 24 | 30.0% | -3.5% | ||
| Q2 24 | 29.9% | -3.1% | ||
| Q1 24 | 21.7% | 1.6% |
| Q4 25 | $0.20 | — | ||
| Q3 25 | $0.15 | $0.01 | ||
| Q2 25 | $0.14 | $0.03 | ||
| Q1 25 | $0.11 | $0.04 | ||
| Q4 24 | $0.45 | $-0.08 | ||
| Q3 24 | $0.15 | $-0.05 | ||
| Q2 24 | $0.13 | $-0.04 | ||
| Q1 24 | $0.08 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $87.6M | $2.2M |
| Total DebtLower is stronger | $72.1M | $250.8M |
| Stockholders' EquityBook value | $477.3M | $162.8M |
| Total Assets | $624.2M | $694.1M |
| Debt / EquityLower = less leverage | 0.15× | 1.54× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $87.6M | — | ||
| Q3 25 | $61.4M | $2.2M | ||
| Q2 25 | $90.3M | $2.2M | ||
| Q1 25 | $71.6M | $2.3M | ||
| Q4 24 | $103.1M | $1.6M | ||
| Q3 24 | $86.7M | $2.9M | ||
| Q2 24 | $88.2M | $3.2M | ||
| Q1 24 | $45.3M | $1.5M |
| Q4 25 | $72.1M | — | ||
| Q3 25 | $72.4M | $250.8M | ||
| Q2 25 | — | $263.3M | ||
| Q1 25 | — | $260.6M | ||
| Q4 24 | $72.3M | $265.2M | ||
| Q3 24 | — | $289.9M | ||
| Q2 24 | — | $303.1M | ||
| Q1 24 | — | $258.8M |
| Q4 25 | $477.3M | — | ||
| Q3 25 | $431.2M | $162.8M | ||
| Q2 25 | $398.3M | $159.8M | ||
| Q1 25 | $373.4M | $154.8M | ||
| Q4 24 | $349.0M | $148.6M | ||
| Q3 24 | $231.9M | $155.0M | ||
| Q2 24 | $188.3M | $158.8M | ||
| Q1 24 | $153.7M | $163.6M |
| Q4 25 | $624.2M | — | ||
| Q3 25 | $568.7M | $694.1M | ||
| Q2 25 | $558.4M | $704.9M | ||
| Q1 25 | $510.6M | $690.7M | ||
| Q4 24 | $488.7M | $668.5M | ||
| Q3 24 | $390.6M | $699.3M | ||
| Q2 24 | $376.4M | $704.7M | ||
| Q1 24 | $350.9M | $671.8M |
| Q4 25 | 0.15× | — | ||
| Q3 25 | 0.17× | 1.54× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.68× | ||
| Q4 24 | 0.21× | 1.78× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 1.91× | ||
| Q1 24 | — | 1.58× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $35.6M | $16.3M |
| Free Cash FlowOCF − Capex | $34.6M | $12.1M |
| FCF MarginFCF / Revenue | 24.8% | 5.9% |
| Capex IntensityCapex / Revenue | 0.8% | 2.1% |
| Cash ConversionOCF / Net Profit | 0.72× | 20.03× |
| TTM Free Cash FlowTrailing 4 quarters | $27.8M | $36.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $35.6M | — | ||
| Q3 25 | $13.3M | $16.3M | ||
| Q2 25 | $21.1M | $-4.5M | ||
| Q1 25 | $-19.7M | $22.3M | ||
| Q4 24 | $50.2M | $33.1M | ||
| Q3 24 | $25.0M | $17.2M | ||
| Q2 24 | $45.6M | $-5.6M | ||
| Q1 24 | $-2.2M | $5.3M |
| Q4 25 | $34.6M | — | ||
| Q3 25 | $-1.1M | $12.1M | ||
| Q2 25 | $18.7M | $-9.2M | ||
| Q1 25 | $-24.4M | $9.5M | ||
| Q4 24 | $47.5M | $24.0M | ||
| Q3 24 | $24.0M | $11.7M | ||
| Q2 24 | $43.6M | $-15.3M | ||
| Q1 24 | $-4.6M | $-2.3M |
| Q4 25 | 24.8% | — | ||
| Q3 25 | -0.8% | 5.9% | ||
| Q2 25 | 15.3% | -4.8% | ||
| Q1 25 | -21.2% | 4.7% | ||
| Q4 24 | 40.4% | 12.4% | ||
| Q3 24 | 20.0% | 6.6% | ||
| Q2 24 | 40.7% | -9.0% | ||
| Q1 24 | -5.6% | -1.2% |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 10.7% | 2.1% | ||
| Q2 25 | 2.0% | 2.5% | ||
| Q1 25 | 4.1% | 6.3% | ||
| Q4 24 | 2.3% | 4.7% | ||
| Q3 24 | 0.9% | 3.2% | ||
| Q2 24 | 1.9% | 5.7% | ||
| Q1 24 | 2.9% | 4.1% |
| Q4 25 | 0.72× | — | ||
| Q3 25 | 0.36× | 20.03× | ||
| Q2 25 | 0.62× | -1.03× | ||
| Q1 25 | -0.73× | 4.63× | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | 1.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
